nach oben

Erschienen in:

18.09.2020 | main topic

SARS-CoV-2: recommendations for treatment in intensive care medicine

verfasst von: Dr. Markus Köstenberger, Prim. Univ.-Prof. Dr. Walter Hasibeder, Dr. Daniel Dankl, Prim. Univ.-Doz. Dr. Reinhard Germann, Prim. Assoc. Prof. Dr. Christoph Hörmann, Univ.-Prof. Dr. Michael Joannidis, Univ.-Prof. Dr. Klaus Markstaller, Dr. Steve-Oliver Müller-Muttonen, Dr. Stefan Neuwersch-Sommeregger, Assoc. Prof. PD Dr. Eva Schaden, Univ.-Prof. Dr. Thomas Staudinger, Ao. Univ.-Prof. Dr. Roman Ullrich, Prim. Univ.-Prof. Dr. Andreas Valentin, MBA, Prim. Univ.-Prof. Dr. Rudolf Likar

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 21-22/2020

Einloggen, um Zugang zu erhalten

Summary

Coronavirus disease 2019 (COVID-19) progresses mildly in most of the cases; however, about 5% of the patients develop a severe acute respiratory distress syndrome (ARDS). Of all COVID-19 patients 3% need intensive care treatment, which becomes a great challenge for anesthesiology and intensive care medicine, medically, hygienically and for technical safety requirements. For these reasons, only experienced medical and nursing staff in the smallest grouping possible should be assigned. For these team members, a consistent use of personal protective equipment (PPE) is essential.

Due to the immense medical challenges, the following treatment guidelines were developed by the ÖGARI (Österreichische Gesellschaft für Anästhesiologie, Reanimation und Intensivmedizin), FASIM (Federation of Austrian Societies of Intensive Care Medicine) and ÖGIAIN (Österreichische Gesellschaft für Internistische und Allgemeine Intensivmedizin und Notfallmedizin).

The recommendations given in this article are to be understood as short snapshots of the moment; all basic guidelines are works in progress and will be regularly updated as evidence levels, new study results and additional experience are gathered.

Vorheriger Artikel Structured ICU resource management in a pandemic is associated with favorable outcome in critically ill COVID‑19 patients

Nächster Artikel Recommendations for extracorporeal membrane oxygenation (ECMO) in COVID-19 patients

Köstenberger M, Hasibeder W, et al. ICU Therapy guideline for the treatment of patients with a SARS CoV2 infection. 2020. https://www.anaesthesie.news/wp-content/uploads/%C3%96GARI-FASIM-%C3%96GIAIN-Guideline-NEU-Covid19-290320.pdf. Accessed 30 Mar 2020.

Alhazzani D, Hylander Moller M, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with Coronavirus disease 2019 (COVID-19). Intensive Care Med. 2020; https://doi.org/10.1007/s00134-020-06022-5.CrossRefPubMedPubMedCentral

Lauer Stephen A, Grantz Kyra H, Bi Qifang, Jones Forrest K, Zheng Qulu, Meredith Hannah R, Azman Andrew S, Reich Nicholas G, Lessler Justin. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 2020;172(9):577–582. https://doi.org/10.7326/M20-0504.CrossRef

NHC. Diagnosis and treatment protocol for novel Coronavirus pneumonia. 2020. http://www.kankyokansen.org/uploads/uploads/files/jsipc/protocol_V7.pdf. Accessed 26 Mar 2020.

Murthy S, Gomersall CD, Fowler RA. Care for critically ill patients with COVID-19. JAMA. 2020; https://doi.org/10.1001/jama.2020.3633.CrossRefPubMedPubMedCentral

Robert Koch Institut. SARS-CoV‑2 Steckbrief zur Coronavirus-Krankheit-2019.. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Steckbrief.html. Accessed 26 Mar 2020.

Bi Q, Wu Y, Mei S, et al. Epidemiology and transmission of COVID-19 in Shenzhen China: analysis of 391 cases and 1,286 of their close contacts. medRxiv. 2020; https://doi.org/10.1101/2020.03.03.20028423.CrossRef

WHO. Situation report.. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed 26 Mar 2020.

Guan W, Zheng-yi H, Yu H, et al. Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med. 2020; https://doi.org/10.1056/NEJMoa2002032.CrossRefPubMedPubMedCentral

10.

Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–9. https://doi.org/10.1001/jama.2020.1585.CrossRefPubMedPubMedCentral

11.

Wu Z, Mc Googan JM. Characteristics of and important lessons from the Coronavirus disease 2019 (COVID-19) outbreak in China. JAMA. 2020; https://doi.org/10.1001/jama.2020.2648.CrossRefPubMedPubMedCentral

12.

Deutsche Röntgengesellschaft. COVID-19. 2020. https://www.drg.de/de-DE/5995/covid-19/. Accessed 8 May 2020.

13.

Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020;2(0):30086–30084. https://doi.org/10.1016/S1473-3099.CrossRef

14.

Sharma R, Agarwal M, Gupta M, Somendra S, Saxena SK. Clinical characteristics and differential clinical diagnosis of novel Coronavirus disease 2019 (COVID-19). In: Saxena S, editor. Coronavirus disease 2019 (COVID-19). Medical virology: from pathogenesis to disease control. Singapore: Springer; 2020.

15.

Papazian L, et al. Formal guidelines: management of acute respiratory distress syndrome. Ann Intensive Care. 2019;9:69. https://doi.org/10.1186/s13613-019-0540-9.CrossRefPubMedPubMedCentral

16.

World Federation of Societies of Anaesthesiologists. Coronavirus—guidance for anaesthesia and perioperative providers. https://www.wfsahq.org/latest-news/latestnews/943-coronavirus-staying-safe

17.

Peng Philip WH, et al. Outbreak of a new coronavirus: what anaesthetists should know. British Journal of Anaesthesia. 2020;124(5):497–501.CrossRefPubMed

18.

Schebesta K, Rössler B. Hygienerichtlinie Coronavirus SARS-CoV2 (COVID-19), Krankenhaushygiene MedUni Wien. Interdisziplinäres Airwaymanagement Team MedUni Wien, Version 1.1., 17.03.2020.

19.

Joannidis M, Forni LG, Klein SJ, et al. Lung-kidney interactions in critically ill patients: consensus report of the Acute Disease Quality Initiative (ADQI) 21 Workgroup. intensive Care Med. 2020;46(4):654–72. https://doi.org/10.1007/s00134-019-05869-7.CrossRefPubMed

20.

Rawson TM, Moore L, Zhu N, et al. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020; https://doi.org/10.1093/cid/ciaa530.CrossRefPubMed

21.

Zhang L, Liu Y. Potential interventions for novel coronavirus in China: a systematic review. J Med Virol. 2020;92:479–90. https://doi.org/10.1002/jmv.25707.CrossRefPubMedPubMedCentral

22.

Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018; https://doi.org/10.1128/mBio.00221-18.CrossRefPubMedPubMedCentral

23.

Brown AJ, Won JJ, Graham RL, et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic delta-coronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res. 2019;169:104541.CrossRefPubMedPubMedCentral

24.

DeWit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci. 2020;117(12):6771–6. https://doi.org/10.1073/pnas.1922083117.CrossRef

25.

Gordon CJ, Tchesnokov EP, Feng JY, et al. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem. 2020; https://doi.org/10.1074/jbc.AC120.013056.CrossRefPubMedPubMedCentral

26.

Ko WC, Rolain JM, Lee NY, et al. Arguments in favour of remdesivir for treating SARS-CoV‑2 infections. Int J Antimicrob Agents. 2020; https://doi.org/10.1016/j.ijantimicag.2020.105933.CrossRefPubMedPubMedCentral

27.

Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020; https://doi.org/10.1016/j.jcrc.2020.03.005.CrossRefPubMedPubMedCentral

28.

Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396):eaal3653. https://doi.org/10.1126/scitranslmed.aal3653.CrossRefPubMedPubMedCentral

29.

Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020; https://doi.org/10.1038/s41467-019-13940-6.CrossRefPubMedPubMedCentral

30.

Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69.CrossRefPubMedPubMedCentral

31.

Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; https://doi.org/10.1038/s41422-020-0282-0.CrossRefPubMedPubMedCentral

32.

Keyaerts E, Vijgen L, Maes P, et al. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004;323:264–8.CrossRefPubMedPubMedCentral

33.

Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: the reality and challenges. J Microbiol Immunol Infect. 2020;53(3):436–43. https://doi.org/10.1016/j.jmii.2020.03.034.CrossRefPubMedPubMedCentral

34.

Harapan H, Itoh N, Yufika A, et al. Coronavirus disease 2019 (COVID-19): a literature review. J Infect Public Health. 2020;13(5):667–73. https://doi.org/10.1016/j.jiph.2020.03.019.CrossRefPubMedPubMedCentral

35.

Horby P, Shen Lim W, Emberson J, et al. Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. RECOVERY Collaborative Group. medRxiv. 2020; https://doi.org/10.1101/2020.06.22.20137273.CrossRef

36.

Johnson RM, Vinetz JM. Dexamethasone in the management of covid-19. BMJ. 2020;370:m2648.CrossRefPubMed

37.

Yang JW, Yang L, Luo RG, Xu JF. Corticosteroid administration for viral pneumonia: COVID-19 and beyond. Clin Microbiol Infect. 2020; https://doi.org/10.1016/j.cmi.2020.06.020.CrossRefPubMedPubMedCentral

38.

Zha L, Li S, Pan L, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust. 2020;212(9):416–20. https://doi.org/10.5694/mja2.50577.CrossRefPubMedPubMedCentral

39.

Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020; https://doi.org/10.1056/NEJMoa2008975.CrossRefPubMedPubMedCentral

Titel: SARS-CoV-2: recommendations for treatment in intensive care medicine
verfasst von: Dr. Markus Köstenberger
Prim. Univ.-Prof. Dr. Walter Hasibeder
Dr. Daniel Dankl
Prim. Univ.-Doz. Dr. Reinhard Germann
Prim. Assoc. Prof. Dr. Christoph Hörmann
Univ.-Prof. Dr. Michael Joannidis
Univ.-Prof. Dr. Klaus Markstaller
Dr. Steve-Oliver Müller-Muttonen
Dr. Stefan Neuwersch-Sommeregger
Assoc. Prof. PD Dr. Eva Schaden
Univ.-Prof. Dr. Thomas Staudinger
Ao. Univ.-Prof. Dr. Roman Ullrich
Prim. Univ.-Prof. Dr. Andreas Valentin, MBA
Prim. Univ.-Prof. Dr. Rudolf Likar
Publikationsdatum: 18.09.2020
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 21-22/2020
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-020-01734-6

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 21-22/2020

Emergency reconstruction of large general hospital under the perspective of new COVID-19 prevention and control

Analysis of Austrian COVID-19 deaths by age and sex

Partially ionized medical oxygen as a supplementary treatment for COVID-19

COVID-19 screening in outpatients with risk factors and healthcare workers

Emergence of coronavirus disease 2019 (COVID-19) in Austria

Impact of COVID-19 on Christmas